Specialized Cancer Center Support Grant

加州大学圣地亚哥分校的摩尔癌症中心是一种基质癌 中心有来自18个大学系的225名成员。加州大学圣地亚哥分校调查人员的同行审查资金是 1.02亿美元(直接成本)，其中3200万美元来自NCI。来自非同行的额外1380万美元 审查来源的结果是，直接成本供资总额为1.158亿美元。一栋新的27万平方英尺多用途住宅 癌症中心大楼于2005年4月开业。它位于加州大学圣迭戈分校的校园里，周围是 其他几家主要的生命科学研究机构和470家生物技术公司在拉霍亚，这是 通常被称为生物技术的“金三角”。MCC是唯一指定的NCI 位于这个多产癌症研究区域的综合性癌症中心。鉴于这一优势，从长远来看 摩尔斯癌症中心的愿景是成为南加州的主要枢纽 发现和测试用于预防、诊断和治疗癌症的新药物。 新的MCC大楼专门设计用于：(1)促进 该中心癌症预防和控制部门、基础科学部门和 临床和转化性研究；(2)在公共和可接近的地点集合广泛的NCI支持的 共享资源，以及(3)充当癌症翻译研究人员的中心聚集地 在南加州的公共和私营部门。因为大楼一年前才开放， 患者对治疗性临床试验的收益增加了一倍多。此应用程序报告11个共享 资源和反映MCC的科学优势和目标的七个研究计划。四 现有课程-癌症生物学、癌症遗传学、癌症预防和控制、癌症症状 控制，三个是新的-血液恶性肿瘤，减少癌症差距，和肿瘤生长， 侵袭和转移。 此应用程序还总结了我们部署源自研究的新疗法的计划 发生在MCC实验室和合作研究所。MCC的领导层，得到了 加州大学圣地亚哥分校行政部门将研究发现及其转化为有意义的研究放在最优先的位置 预防、改善和消除癌症负担的进展。

The Moores Cancer Center [MCC] at the University of California, San Diego [UCSD] is a matrix cancer center with 225 members from 18 university departments. Peer-reviewed funding for UCSD investigators is $102 million (direct cost), of which $32 million originates from the NCI. An additional $13.8 million from nonpeer reviewed sources results in total direct cost funding of $115.8 Million. A new 270,000 sq ft multipurpose Cancer Center building opened in April, 2005. It is located on the UCSD campus, surrounded by several other major life science research institutes and 470 biotechnology companies in La Jolla, which is commonly referred to as the "Golden Triangle" of biotechnology. The MCC is the only NCI designated comprehensive cancer center in this prolific cancer research region. Given this advantage, the long term vision for the Moores Cancer Center is to become the major hub in Southern California for the discovery and testing of new agents for the prevention, diagnosis and treatment of cancer. The new MCC building was specifically designed to: (1) stimulate interdisciplinary collaboration between physicians and scientists in the Center's Divisions of Cancer Prevention and Control, Basic Science, and Clinical and Translational Research; (2) assemble in a common and accessible site the extensive NCIsupported Shared Resources, and (3) act as a central gathering site for cancer translational researchers within the public and private sectors of Southern California. Since the building's opening only one year ago, patient accrual to therapeutic clinical trials has more than doubled. This application reports on 11 Shared Resources and seven Research Programs which reflect the scientific strengths and goals of the MCC. Four programs are existing - Cancer Biology, Cancer Genetics, Cancer Prevention and Control, Cancer Symptom Control, and three are new- Hematologic Malignancies, Reducing Cancer Disparities, and Tumor Growth, Invasion and Metastasis. This application also summarizes our plans for the deployment of new therapeutics originating from research occurring in MCC laboratories and collaborating institutes. The leadership of the MCC, supported by the UCSD administration, places the highest priority on research discovery and its translation into meaningful advances to prevent, ameliorate and eliminate the burden of cancer.